Formulation and Physicochemical Evaluation of a 3% Cream Using Crude 70% Ethanolic Extract of *Morus alba* L. Leaves for Skin Hyperpigmentation

Shahab Edalatian Zakeri^{1,2}, Abbas Hadjiakhoondi^{1,3}, Saman Ahmad Nasrollahi^{2,*}, Mahdi Vazirian^{1,3} and Atefeh Naeimifar⁴

¹Department of Pharmacognosy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

²Cosmeceutical and Hygienic Formulation Lab, Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran

³Medicinal Plants Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

⁴Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

*Corresponding author: Center for Research and Training in Skin Diseases and Leprosy (CRTSDL), Tehran University of Medical Sciences (TUMS), #415 Taleqani Ave, Tehran, Iran. Tel: +98-2188963804, Fax: +98-2188963804, Email: snasrollahi@tums.ac.ir

Received 2021 April 14; Revised 2021 May 11; Accepted 2021 May 17.

Abstract

Background: Treatment of hyperpigmentation disorders is a challenge because of the side effects of current topical treatments. Thus, research for potent alternatives, especially of herbal origin, with comparable potency and less side effects is ongoing. *Morus alba* L. is a perennial plant with multiple established pharmacological effects, including antimelanogenesis effect. This effect has been demonstrated from different parts of the plant, including twigs, root barks, and leaves by measuring tyrosinase inhibition, melanin content, and melanin index, and it has been attributed to phenolic compounds such as oxyresveratrol and moracin M, to name a few. However, no study has considered formulating the total phenolic compounds from the leaves of this plant so far.

Objectives: The aim of this study was to extract phenolic compounds of leaves with repeated maceration using 70% ethanol, formulate the crude extract, inspect its physicochemical stability under accelerated conditions, and assay for microbial growth and active phenolic compounds.

Methods: Total phenolic compounds were extracted using 70% ethanol with repeated maceration, and then they were concentrated. The extract was then assayed for total phenolic content using Folin-Ciocalteu's reagent. A 3% cream of this extract was manufactured, and its physicochemical parameters, microbial growth, preservative effectiveness, and total phenolic content were examined.

Results: The prepared 3% cream was completely stable and homogeneous during the accelerated conditions and passed the physicochemical, total phenolic content, and microbial tests.

Conclusions: The manufactured cream is a promising formulation for in vivo use as a skin lightening agent.

Keywords: *Morus alba* L., Hyperpigmentation, Physicochemical Evaluation, Topical Formulation

1. Background

Hyperpigmentation disorders of the skin are a group of conditions that cause darkening of the skin, with melasma and post-inflammatory hyperpigmentation (PIH) being the most common types. The exact etiologies of melasma and PIH are unknown, but external factors such as prolonged sun exposure, women's hormonal fluctuations, and drug adverse effects have been indicated (1, 2). These disorders are of great psychological importance since they can negatively impact the quality of life and emotional well-being of an individual. This importance has been demonstrated in various studies (2).

First-line treatment of these disorders is usually carried out topically with hydroquinone, which is commonly used concomitantly with retinoids and sometimes topical corticosteroids. Hydroquinone interferes with melanin synthesis, while retinoids increase keratinocyte turnover, and corticosteroids are used to reduce the inflammation caused by the retinoids and hydroquinone. Additionally, corticosteroids have a non-selective inhibitory effect on melanogenesis. However, these agents and other commonly utilized medicines frequently cause skin irritation. In addition, hydroquinone may cause contact dermatitis, and long-term usage of this drug is associated with con-

junctival melanosis, nail discoloration, and a rare, yet serious adverse effect called exogenous ochronosis. On the other hand, chronic topical corticosteroid therapy may cause acne, epidermal atrophy, and striae (3, 4). Accordingly, there has been an ongoing research to find alternatives, especially herbal ones, for hydroquinone and other compounds. Examples of such alternatives include soy extract, licorice extract, arbutin, green tea, and Aloe vera; some of these compounds have been used as empiric therapy in traditional medicine (5).

Morus alba L. (common name: white mulberry) is a Chinese tree utilized for fodder and silk production. Traditionally, different parts of the plant, such as leaves, fruits, and root bark, have been used for treating conditions such as common cold, pain, high blood pressure, diabetes, urinary incontinence, and constipation (6). It has a wide range of active constituents, including flavonoids, anthocyanins, stilbenoids, terpenoids, alkaloids, phenolic acids, and coumarins. Some of the many pharmacological effects of the plant that have been demonstrated in various studies are antioxidant, anti-inflammatory, antimicrobial, antidiabetic, and antihyperlipidemic effects.

Skin lightening properties have been demonstrated by crude extracts or isolated phenolic compounds from root barks, twigs, and leaves of the plant, both in vitro and in vivo (7). Some of the isolated compounds include oxyresveratrol and its mono- and di-glycosylated (mulberroside A) forms, moracin M and its glycosylated form mulberroside F, kaempferol, quercetin, and its glycosylated form isoquercetin, rutin, maclurin, resveratrol, and morin (8-12). So far, no study has attempted to develop a suitable formulation from the leaves of white mulberry, perform its stability studies, assess microbial growth, and assay total phenolic compounds as the active ingredients.

2. Objectives

The aim of this study was to develop a topical formulation obtained from crude (70% ethanolic) extract of white mulberry leaves and evaluate its stability, physicochemical properties, microbial growth, and preservative effectiveness under accelerated conditions.

3. Methods

3.1. Materials

White mulberry leaves were gathered in May 2017 from the green space of Tehran, Iran by the main author and later authorized by a certified botanist at the herbarium

of the Faculty of Pharmacy of Tehran University of Medical Sciences (voucher number: TEH-6599).

Ninety-six percent ethyl alcohol and titanium dioxide were bought from Zakariajahrom (Iran) and Sepidaj (Iran), respectively. Folin-Ciocalteu's reagent, cetearyl alcohol, cetyl palmitate, isopropyl alcohol, methylparaben, propylparaben, isopropyl myristate, benzyl alcohol, ethylenediaminetetraacetic acid (EDTA), Span 60, Tween 80, gallic acid, sodium bicarbonate, and hexane were purchased from Merck (Germany). Sepigel 305 was obtained from Seppic (USA). Deionized water was prepared freshly as required.

3.2. Preparation of the Extract

First, the leaves were dried under room temperature at 25°C in the shade and then crushed slightly by hand. To extract the total phenolic contents, 70% ethanol was used. Seventy percent ethanol was chosen over the 96% ethanol as the solvent after determining the extraction yield for 1 g of dried leaves by measuring the dried extract weight. Next, repeated maceration was performed for 1 kg of dried leaves using 70% ethanol. The process was carried out three times, each for 72 hours. Finally, the extract was concentrated using rotary evaporator Heidolph (Model: Hei-VAP Value Hand Lift; Germany). The extract was stored in a closed glass container in refrigerator at $7 \pm 1^\circ\text{C}$ and was used as needed.

3.3. Quantification of the Phenolic Content of the Extract

Total phenolic content (TPC) of the extract was quantified using a slightly modified version of the original Folin-Ciocalteu's method (13). Triplicate concentrations of the standard gallic acid in 70% ethanol (10, 20, 40, and 80 $\mu\text{g/mL}$) were used to plot a calibration curve. One mL of the suitable concentration of the extract (500 $\mu\text{g/mL}$) was added to three test tubes. This concentration was found after trial and error to fit linear range of the calibration curve. Another tube was dedicated as the negative control, containing only 1 mL of 70% ethanol. Then, 2 mL of the Folin-Ciocalteu's reagent (diluted 1:10 with deionized water) was added to the tubes. After 10 minutes, 1.5 mL of 7.5% (w/v) sodium bicarbonate was added to each tube. All tubes were incubated in the dark for 30 minutes. Finally, their absorption was measured at 765 nm using Optizen 2120UV Plus (Korea) spectrophotometer. The absorptions were put into calibration curve formula, and the TPC was expressed in terms of gallic acid equivalent (GAE) mg/g of the extract.

3.4. Preparation of Cream

The aqueous phase consisted of the plant extract, Tween 80, methyl and propylparaben, benzyl alcohol, EDTA, and deionized water, and the lipid phase comprised TiO_2 , Span 60, cetearyl alcohol, isopropyl alcohol, and isopropyl myristate. First, both phases were heated to $75 \pm 1^\circ\text{C}$. A small portion of the aqueous phase was separated after reaching $45 \pm 1^\circ\text{C}$ and later added to the formulation to prevent possible decomposition of active compounds. The initial cream was prepared by the addition of the aqueous phase to the oily phase while being stirred at 1000 RPM using IKA RW 20 (Germany) stirrer. Next, the mixture was homogenized using MICCRA D-15 (Germany) homogenizer. Finally, Sepigel 305 was added to the mixture, and the finished cream was further stirred at 1000 RPM until it was cooled down to the room temperature.

3.5. Emulsion Type Determination

Emulsion type was determined by performing three tests. First, electrical conductivity was measured using the conductivity meter (Jenway 4070; UK), in which paraffin was used as control. In addition, a sample of cream was examined under a microscope (Zeiss, Germany) and was investigated for oil or water droplets. Finally, a dilution test was performed to confirm the findings of previous tests. In this test, a sample of cream was diluted using deionized water. The type of emulsion (water/oil or oil/water) was determined by assessing the solubility and homogeneity of cream in water.

3.6. Stability Studies

The finished product was subjected to accelerated stability tests at $40 \pm 2^\circ\text{C}/75 \pm 5\% \text{ RH}$ for a total of three months. During this period, analysis of physicochemical parameters as well as microbial assessment and phenolic screening were performed upon manufacturing the cream and at 1st and 3rd months, subsequently.

3.7. Physical Parameters

The manufactured cream was examined for phase separation and changes in odor, color, homogeneity, and consistency. Moreover, pH, density, and viscosity were measured.

3.7.1. Determination of pH

The digital pH meter (Metrohm 827-Swiss) was used to measure the pH of the preparation. Examinations were repeated in triplicate. The pH meter was calibrated using standard buffer solutions (pH = 4 and 7) before use.

3.7.2. Density

The density of a substance is its mass per unit volume. The exact volume of pycnometer was measured by filling it completely with water, and the sides were lightly tapped to eliminate the air bubbles. The container was weighted full of a cream, and simply the density was examined.

$$\rho = m/V$$

ρ = density, m = mass, V = volume.

3.7.3. Viscosity

The cream viscosity was assessed by a Polyvisc Viscometer (Brookfield-USA) using a spindle R6 at 100 rpm. Viscosity measurements were carried out at room temperature ($25 \pm 2^\circ\text{C}$). All measurements were performed in triplicate.

Viscosity in centipoises (cps) = Dial reading $\times$ factor

3.8. Microbial Assessments

For microbial assessment, 10 g of cream was mixed with 3 g of sterile polysorbate 80; then, 24 g of 10% tween 60 water solution was added to the TSB medium to diagnose the bacteria (mixture 1). Plates with 25 - 250 colonies were calculated, and the average number of colony forming units (CFU)/g was counted. Two dilutions (0.1, 0.01) with the TSB culture medium were prepared, and 1-2 mL of pre-prepared dilution was added to 2 sterile plates containing 10 - 20 mL of TSA culture medium and incubated for 24 - 48 hours at 30°C - 35°C (pure plate). One mL of 0.1 dilutions for fungal counting allowed the agar to solidify at $25 \pm 2^\circ\text{C}$, then incubated at 20°C - 25°C for 5 - 7 days. Colonies were counted after the incubation; all preparations were carried out in triplicate. All microbial counts were carried out via pour plate and incubated for 3 days, and then counting was performed. Counting was approved in plates containing fewer than 100 colonies for microbial count (TAMC) and in those comprising less than 10 colonies for fungal count (TYMC).

Salmonella Count: Colonies were grown in Rappaport Vassiliadis *Salmonella* Enrichment broth medium and counted after 18 - 48 hours of incubation at 30°C - 35°C .

Enterobacteriaceae Count: Colonies were counted after 18 - 24 hours of incubation at 30°C - 35°C .

Candida albicans Count: To achieve this aim, 10 mL of mixture 1 was added to 100 mL Sabouraud Dextrose agar (SDA) medium culture and incubated at 30°C - 35°C for 3 - 5 days. After growing the colonies, it was incubated for 24 - 48 hours.

Escherichia coli Count: Colonies were grown in MacConkey broth medium and counted after 18 to 72 hours of incubation at 30°C - 35°C .

Pseudomonas aeruginosa Count: Mixture 1 was grown in Cetrimide agar and incubated at 30°C-35°C for 18-72 hours.

Staphylococcus aureus Count: After having any *S. aureus* growth in mixture 1, it was cultured in Mannitol Salt agar and incubated at 30°C - 35°C for 18 - 72 hours, and the colonies were counted.

3.9. Preservative Effectiveness Test

A standardized inoculum containing three bacteria (*P. aeruginosa*, *E. coli*, and *S. aureus*), a yeast (*C. albicans*), and a mold (*Aspergillus niger*) was mixed with the liquid product. The mixture comprising 0.05% of polysorbate 80 was added to adequate sterile buffer phosphate (pH = 7.2) to gain a count of about 1×10^8 CFU per mL. The absorption of the inoculum was seen at 580 nm. Then, 10 g of preparation was added to 90 mL buffer phosphate (mixture 2), and 0.1 and 0.01 dilutions of mixture 2 was prepared. Then, 1 mL of 0.1 and 0.01 dilutions was added to a sterile plate comprising 15-20 mL of the TSA medium, which cooled to 45°C, and incubated for 24 - 48 hours at 30°C - 35°C. The fungal process was alike to the above, excluding that the SDA culture with 0.1 dilution was incubated for 5 - 7 days at 20°C - 25°C. Positive and negative controls were used during the test. Microbiological examinations were performed for preparations at 25°C after 14 and 28 days of the formulation.

3.10. Quantification of Phenolic Content in the Finished Product

In order to extract active ingredients from the finished product, 1 g of the cream was weighed and added into 50 mL of 70% ethanol. The supernatant was removed three times by decantation using 50 mL of hexane. Finally, the supernatant was separated and concentrated using rotary evaporator. A concentration of 1000 µg/mL of extracted material was prepared each month, and 1 mL of it was used for quantification of total phenolic according to the above-mentioned method plus a negative control. The measurements were done in triplicates.

3.11. Statistical Analysis

Values in all experiments are represented as mean $\pm$ SD of at least three independent experiments. Statistical analysis was performed by repeated measurement analysis of variance (ANOVA) test. The significant level was also set as $P < 0.05$.

4. Results and Discussion

The extraction yield for 1 g of dried leaves was 3.4% for 96% ethanol and 7.5% for 70% ethanol. The extraction yield

for the main maceration for 1 kg of the dried leaves was 34.3%. The extract was a dark green viscous liquid. The cream was light green in color and homogenous in texture upon preparation. The emulsion electrical conductivity was 0.33 millisiemens/cm, while paraffin showed zero electrical conductivity, indicating oil in water emulsion. The dispersion of oil droplets in the aqueous phase was recognized in the microscopic images (Figure 1).

The formulation showed no variation in color, odor, pH, and phase separation during the specified time span. The pH of the cream at the initial, 1st, and 3rd months was 6.3 ± 0.15 , 6.05 ± 0.02 , and 5.83 ± 0.037 , respectively (Table 1). Viscosity at the initial, 1st, and 3rd months was 4240 ± 32.50 cP, 6810 ± 79.57 cP, and 7720 ± 40.51 cP, respectively. Lastly, the density of cream at the initial, 1st, and 3rd months was 0.98 ± 0.01 , 0.95 ± 0.005 , and 0.96 ± 0.01 g/cm³, respectively. Microbial assessment at the initial, 1st, and 3rd months showed less than 10 colonies for respective bacteria and fungi, which indicates adequate and efficient antimicrobial activity. The standard curve equation was $y = 0.0098x + 0.074$, where $R^2 = 0.9957$ (Figure 2). There were no significant changes within stability time in assay, pH, density, and viscosity (P-value of all following physico-chemical characteristics was greater than 0.05).

The total phenolic contents (mg.GAE/g of extract) in the cream at the initial, 1st, and 3rd months were calculated to be 24.90 ± 0.58 mg/g, 48.61 ± 1.38 mg/g, and 38.61 ± 1.13 mg, respectively (Table 1).

The current body of evidence attributes anti-melanogenesis activity of the plant to its phenolic compounds. Thus, we manufactured a formulation using crude 70% ethanolic extract of leaves of *Morus alba* L. and analyzed its phenolic content and stability. Using crude extract provides a possible synergism between phenolic compounds as opposed to fractionating to a single compound. For sufficient extraction of phenolic compounds, we used 70% ethanol as the solvent; compared to 96% ethanol, it had a better extraction yield measured by dry weight of extracts. Since concentrated extract was quite viscous, adhesive, and staining, we tried oven drying to obtain a more suitable form, but it resulted in no significant weight difference, much less than 10%, so the concentrated extract remained without any changes. Our formula was an O/W cream which had a light and non-oily texture. The physicochemical properties of the cream, namely pH, viscosity, and density, were assessed, as well as total phenolic content screening using Folin-Ciocalteu's method. All these properties were satisfactory. The O/W cream microbial status was also in accordance with the

Figure 1. Oil droplets in the aqueous phase (40 × magnification)

requirements of USP 40-NF 35 guidelines, including microbial enumeration tests of non-sterile products, tests for specified organisms, and antimicrobial effectiveness testing. All antimicrobial excipients were in the range according to the handbook of pharmaceutical excipients (14-16).

The concentrated extract itself was screened for total

phenolic content as a reference point. The total phenolic content of the formulation surprisingly increased relative to initial measurement. Thus, the concentrated extract was screened again and compared to the reference point to make sure the prolonged period of storage had not decreased the total phenolic content. Again, the concentrated extract showed an increase relative to the initial ref-

Figure 2. Calibration curve of different concentrations of gallic acid in ethanol 70%, n=3

Table 1. Results of Physicochemical Stability and Microbial and Phenolic Assessment^a

Test	Period of storage (40°C ± 2°C, 75% RH ± 5% RH)			Standard
	Initial	1st Month	3rd Month	
Description	Complies	Complies	Complies	Light green cream, homogenous cream mass
Odor	Complies	Complies	Complies	Characteristic order
pH	6.3 ± 0.15	6.05 ± 0.02	5.83 ± 0.037	5-7
Viscosity, cP	4240 ± 32.50	6810 ± 79.57	7720 ± 40.51	NLT* 4000, NMT** 10000
Density, g/cm³	0.98 ± 0.01	0.95 ± 0.005	0.96 ± 0.01	0.90 - 1
Total phenolic content, GAE mg/g	24.90 ± 0.58	48.61 ± 1.38	38.61 ± 1.13	
Microbial enumeration and tests for specific microorganisms				
Total bacterial count, CFU/g	< 10	< 10	< 10	NMT 100
Total fungi and yeast count, CFU/g	< 10	< 10	< 10	NMT 10
<i>P. aeruginosa</i>	Neg.	Neg.	Neg.	Must be negative
<i>S. aureus</i>	Neg.	Neg.	Neg.	Must be negative
<i>E. coli</i>	Neg.	Neg.	Neg.	Must be negative
<i>Salmonella</i> spp.	Neg.	Neg.	Neg.	Must be negative
<i>Candida albicans</i>	Neg.	Neg.	Neg.	Must be negative
Antimicrobial Effectiveness test	Ok	Ok	Ok	Bacteria: NLT 2 log reduction from the initial count at day 14, and no increase from day 14 count to day 28. Yeast and Mold: No increase from the initial count at days 14 and 28.

^a All experiments was performed in triplicate and written as a mean ± SD.

^b *, Not less than; **, not more than.

erence measurement. The possible reasons are breakdown or hydrolysis of large polyphenols such as galloocatechin gallates into smaller phenols, alteration in interactions between excipients and phenolic components, and/or release of bound phenolic functional groups. Moreover, mixing and homogenizing the cream can cause further breaking of cellular structures since it was a crude extract, thus making reducing phenols more available for Folin-Ciocalteu's reaction.

5. Conclusions

Hyperpigmentation treatment requires the long-term usage of topical drugs and current treatments face challenges as their aggressiveness and chronic use may cause side effects such as irritant dermatitis, exogenous ochronosis, and epidermal atrophy. Consequently, research has been carried out to find substitutes, herbal substitutes in particular. Different parts of the plant *Morus alba* L. has demonstrated promising whitening effects, which has been attributed to its phenolic compounds, such as oxyresveratrol and moracin, among many others. The crude extract from the leaves of this plant has never been formulated and undergone stability tests. Hence, in this study, we formulated and examined physicochemical properties of a cream based on the leaves of white mulberry. The manufactured formulation passed the respective stability tests, microbial assessment, and phenolic screening. In brief, the finished product passed the respective accelerated stability tests, and is therefore a promising formulation to be tested as a skin whitening agent.

Footnotes

Authors' Contribution: Shahab Edalatian Zakeri and Atefeh Naeimifar carried out the experiments and formulated the topical cream. Shahab Edalatian Zakeri and Atefeh Naeimifar wrote the initial draft. Saman Ahmad Nasrollahi designed and supervised the formulatuin and physicochemical assessment parts. Abbas Hadjiakhoondi and Mahdi Vazirian designed and supervised the botanical assessments.

Conflict of Interests: The authors declare no conflict of interests.

Funding/Support: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

1. Costin GE, Hearing VJ. Human skin pigmentation: melanocytes modulate skin color in response to stress. *FASEB J*. 2007;**21**(4):976–94. doi: [10.1096/fj.06-6649rev](https://doi.org/10.1096/fj.06-6649rev). [PubMed: [17242160](https://pubmed.ncbi.nlm.nih.gov/17242160/)].
2. Grimes PE. Management of hyperpigmentation in darker racial ethnic groups. *Semin Cutan Med Surg*. 2009;**28**(2):77–85. doi: [10.1016/j.sder.2009.04.001](https://doi.org/10.1016/j.sder.2009.04.001). [PubMed: [19608057](https://pubmed.ncbi.nlm.nih.gov/19608057/)].
3. Kaufman BP, Aman T, Alexis AF. Postinflammatory Hyperpigmentation: Epidemiology, Clinical Presentation, Pathogenesis and Treatment. *Am J Clin Dermatol*. 2018;**19**(4):489–503. doi: [10.1007/s40257-017-0333-6](https://doi.org/10.1007/s40257-017-0333-6). [PubMed: [29222629](https://pubmed.ncbi.nlm.nih.gov/29222629/)].
4. Ogbechie-Godec OA, Elbuluk N. Melasma: an Up-to-Date Comprehensive Review. *Dermatol Ther (Heidelb)*. 2017;**7**(3):305–18. doi: [10.1007/s13555-017-0194-1](https://doi.org/10.1007/s13555-017-0194-1). [PubMed: [28726212](https://pubmed.ncbi.nlm.nih.gov/28726212/)]. [PubMed Central: [PMC5574745](https://pubmed.ncbi.nlm.nih.gov/PMC5574745/)].
5. Leyden JJ, Shergill B, Micali G, Downie J, Wallo W. Natural options for the management of hyperpigmentation. *J Eur Acad Dermatol Venereol*. 2011;**25**(10):1140–5. doi: [10.1111/j.1468-3083.2011.04130.x](https://doi.org/10.1111/j.1468-3083.2011.04130.x). [PubMed: [21623927](https://pubmed.ncbi.nlm.nih.gov/21623927/)].
6. United States Department of Agriculture. *The PLANTS Database*. 2019. Available from: <https://plants.usda.gov/core/profile?symbol=MOAL>.
7. Chan EW, Lye PY, Wong SK. Phytochemistry, pharmacology, and clinical trials of *Morus alba*. *Chin J Nat Med*. 2016;**14**(1):17–30. doi: [10.3724/SP.J.1009.2016.00017](https://doi.org/10.3724/SP.J.1009.2016.00017). [PubMed: [26850343](https://pubmed.ncbi.nlm.nih.gov/26850343/)].
8. Kim YM, Yun J, Lee CK, Lee H, Min KR, Kim Y. Oxyresveratrol and hydroxystilbene compounds. Inhibitory effect on tyrosinase and mechanism of action. *J Biol Chem*. 2002;**277**(18):16340–4. doi: [10.1074/jbc.M200678200](https://doi.org/10.1074/jbc.M200678200). [PubMed: [11864987](https://pubmed.ncbi.nlm.nih.gov/11864987/)].
9. Park KT, Kim JK, Hwang D, Yoo Y, Lim YH. Inhibitory effect of mulberroside A and its derivatives on melanogenesis induced by ultraviolet B irradiation. *Food Chem Toxicol*. 2011;**49**(12):3038–45. doi: [10.1016/j.fct.2011.09.008](https://doi.org/10.1016/j.fct.2011.09.008). [PubMed: [21946069](https://pubmed.ncbi.nlm.nih.gov/21946069/)].
10. Chang LW, Juang LJ, Wang BS, Wang MY, Tai HM, Hung WJ, et al. Antioxidant and antityrosinase activity of mulberry (*Morus alba* L.) twigs and root bark. *Food Chem Toxicol*. 2011;**49**(4):785–90. doi: [10.1016/j.fct.2010.11.045](https://doi.org/10.1016/j.fct.2010.11.045). [PubMed: [21130832](https://pubmed.ncbi.nlm.nih.gov/21130832/)].
11. Jeong JY, Liu Q, Kim SB, Jo YH, Mo EJ, Yang HH, et al. Characterization of Melanogenesis Inhibitory Constituents of *Morus alba* Leaves and Optimization of Extraction Conditions Using Response Surface Methodology. *Molecules*. 2015;**20**(5):8730–41. doi: [10.3390/molecules20058730](https://doi.org/10.3390/molecules20058730). [PubMed: [26007176](https://pubmed.ncbi.nlm.nih.gov/26007176/)]. [PubMed Central: [PMC6272263](https://pubmed.ncbi.nlm.nih.gov/PMC6272263/)].
12. Lee SH, Choi SY, Kim H, Hwang JS, Lee BG, Gao JJ, et al. Mulberroside F isolated from the leaves of *Morus alba* inhibits melanin biosynthesis. *Biol Pharm Bull*. 2002;**25**(8):1045–8. doi: [10.1248/bpb.25.1045](https://doi.org/10.1248/bpb.25.1045). [PubMed: [12186407](https://pubmed.ncbi.nlm.nih.gov/12186407/)].
13. Singleton VL, Rossi JA. Colorimetry of total phenolics with phosphomolybdic-phosphotungstic acid reagents. *Am J Enol Viticult*. 1965;**16**(3):144–58.
14. Wang W, Zu Y, Fu Y, Efferth T. In vitro antioxidant and antimicrobial activity of extracts from *Morus alba* L. leaves, stems and fruits. *Am J Chin Med*. 2012;**40**(2):349–56. doi: [10.1142/S0192415X12500279](https://doi.org/10.1142/S0192415X12500279). [PubMed: [22419428](https://pubmed.ncbi.nlm.nih.gov/22419428/)].
15. Akhtar N, Hisham J, Khan HMS, Khan BA, Mahmood T, Saeed T. Whitening and antierythemal effect of a cream containing *Morus alba* extract. *Hygeia J D Med*. 2012;**4**(1):97–103. doi: [10.1155/2015/709628](https://doi.org/10.1155/2015/709628).
16. Rowe RC, Sheskey PJ, Quinn ME. *Handbook of pharmaceutical excipients*. 8th ed. London: Pharmaceutical Press; 2009.